Medifast MED Insider Ownership

Updated Nov 13, 2026

In the last 12 months, insiders at Medifast made open-market purchases of $1.74 million (148.86K shares) and open-market sales of $226,289 (19.09K shares).

• Behind Medifast's open-market trades in the past 12 months were 3 insiders buying and one insider selling.
• Among Medifast's insiders, the largest open-market purchases in the past 12 months were by Parsa Kiai (Director), totaling $1.5 million (126.18K shares), most recently on November 4, 2026.
• On the sell side, Daniel R. Chard (Director) led open-market sales of Medifast stock over the past 12 months with $226,289 (19.09K shares), most recently on September 29, 2026.
• Apart from open-market trades, MED insiders received 114.04K shares in stock awards and gave up 35.56K shares to cover taxes or exercise prices in the past 12 months.
• Business Quant data puts insider holdings in MED at 667.32K shares across insiders' latest Form 4 filings, up 0.30% from 665.32K shares at the end of Q2 2026.
• Direct holdings account for 493.71K shares (73.98%) of MED's insider total, and indirect holdings through trusts, partnerships and family members for 173.61K shares (26.02%).
• The insider holdings in Medifast belong to 10 insiders who have reported on Form 4 within the past two years.
• MED's three largest insider shareholders, per their latest Form 4 filings, are Daniel R. Chard (Director, 336.52K shares), James P. Maloney (Chief Financial Officer, 73.03K shares) and Jeffrey J. Brown (Director, 42.81K shares).
• Daniel R. Chard alone accounts for 50.43% of the shares held by Medifast insiders.
• Institutions accounted for 73.83% of MED's outstanding shares in Q2 2026, insiders about 5.97% per their latest Form 4 filings, and other investors, including the public, about 20.20%.
• A total of 16 Form 4 filings with transactions in Medifast stock were made over the past 12 months, by 9 insiders.
• Insider figures for MED include Form 4 filings through November 6, 2026.